IN2014DN06869A - - Google Patents
Info
- Publication number
- IN2014DN06869A IN2014DN06869A IN6869DEN2014A IN2014DN06869A IN 2014DN06869 A IN2014DN06869 A IN 2014DN06869A IN 6869DEN2014 A IN6869DEN2014 A IN 6869DEN2014A IN 2014DN06869 A IN2014DN06869 A IN 2014DN06869A
- Authority
- IN
- India
- Prior art keywords
- subclasses
- classes
- pharmaceutically acceptable
- treatment
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Abstract
The present invention provides compounds having the general structural formula (I) and pharmaceutically acceptable derivatives thereof as described generally and in classes and subclasses herein and additionally provides pharmaceutical compositions thereof and methods for the use thereof for the treatment of any of a number of conditions or diseases involving abnormal or excessive fibrosis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261632582P | 2012-01-26 | 2012-01-26 | |
PCT/US2013/023324 WO2013112959A1 (en) | 2012-01-26 | 2013-01-26 | Antifibrotic compounds and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN06869A true IN2014DN06869A (en) | 2015-05-22 |
Family
ID=48873985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN6869DEN2014 IN2014DN06869A (en) | 2012-01-26 | 2013-01-26 |
Country Status (15)
Country | Link |
---|---|
US (4) | US9040555B2 (en) |
EP (2) | EP2807160B1 (en) |
JP (1) | JP6152389B2 (en) |
CN (1) | CN104136436B (en) |
AU (1) | AU2013211888B2 (en) |
CA (1) | CA2862692C (en) |
DK (1) | DK2807160T3 (en) |
ES (1) | ES2748873T3 (en) |
HK (1) | HK1203502A1 (en) |
HU (1) | HUE046368T2 (en) |
IL (2) | IL233727A (en) |
IN (1) | IN2014DN06869A (en) |
PL (1) | PL2807160T3 (en) |
PT (1) | PT2807160T (en) |
WO (1) | WO2013112959A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9597321B2 (en) * | 2012-01-26 | 2017-03-21 | Angion Biomedica Corp. | Antifibrotic compounds and uses thereof |
DK2807160T3 (en) | 2012-01-26 | 2019-10-14 | Angion Biomedica Corp | ANTIFIBROTIC COMPOUNDS AND APPLICATIONS THEREOF |
US20150105380A1 (en) * | 2013-09-23 | 2015-04-16 | Angion Biomedica Corp. | Methods and uses of compounds for treating disease |
CN104387385B (en) * | 2014-11-14 | 2016-03-23 | 苏州和健医药科技有限公司 | 6-carboxylate methyl ester-2-oxygen-7-azaindole and preparation method thereof and application |
EP3363799A4 (en) * | 2015-11-12 | 2018-12-05 | LG Chem, Ltd. | Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof |
JP7039480B2 (en) * | 2016-03-08 | 2022-03-22 | レスピバート・リミテツド | Indole derivatives and their use as protein kinase inhibitors |
JP2019519543A (en) * | 2016-06-07 | 2019-07-11 | デルマヴァント サイエンシーズ ゲーエムベーハーDermavant Sciences Gmbh | Topical formulations of PDE-4 inhibitors and methods of their use |
US20220401423A1 (en) * | 2019-11-20 | 2022-12-22 | Angion Biomedica Corp. | Methods for treating inflammatory bowel disease |
WO2022006278A1 (en) * | 2020-07-01 | 2022-01-06 | Angion Biomedica Corp. | Reducing fibrosis and treating related diseases, disorders, and conditions |
US20230312561A1 (en) * | 2020-07-01 | 2023-10-05 | Angion Biomedica Corp. | Solid forms of (z)-methyl 3-(((4-(n-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxo-2,3-dihydro-1h-pyrrolo[2,3-b]pyridine-6-carboxylate and salts thereof |
WO2022006277A1 (en) * | 2020-07-01 | 2022-01-06 | Angion Biomedica Corp. | Methods for treatment of fibrotic kidney diseases |
WO2022165092A1 (en) * | 2021-01-29 | 2022-08-04 | Angion Biomedica Corp. | Methods for treatment of fibrotic diseases |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
AU4685799A (en) | 1998-06-17 | 2000-01-05 | Geron Corporation | Telomerase inhibitors |
GB9904995D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Substituted aza-oxindole derivatives |
US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
UA75054C2 (en) | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Substituted in position 6 indolinones, producing and use thereof as medicament |
US6762180B1 (en) * | 1999-10-13 | 2004-07-13 | Boehringer Ingelheim Pharma Kg | Substituted indolines which inhibit receptor tyrosine kinases |
JP2003531895A (en) | 2000-05-02 | 2003-10-28 | スージェン・インコーポレーテッド | (2-Oxindole-3-yridenyl) acetic acid derivatives and their use as protein kinase inhibitors |
JP2006510727A (en) * | 2002-11-15 | 2006-03-30 | エクセリクシス, インク. | Kinase modulator |
PE20060777A1 (en) * | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES |
WO2008138184A1 (en) | 2007-05-14 | 2008-11-20 | Shanghai Hengrui Pharmaceutical Co.Ltd. | Derivatives of pyrroloazacycles, the method of making them and the use thereof as inhibitors of protein kinases |
WO2008138232A1 (en) | 2007-05-14 | 2008-11-20 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof |
WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
TWI440638B (en) | 2007-10-30 | 2014-06-11 | Otsuka Pharma Co Ltd | Heterocyclic compound and pharmaceutical composition thereof |
WO2010088000A2 (en) | 2009-02-02 | 2010-08-05 | Angion Biomedica Corp. | Antifibrotic compounds and uses thereof |
WO2010144959A1 (en) * | 2009-06-18 | 2010-12-23 | Fibrotech Therapeutics Pty Ltd | Analogues of anti-fibrotic agents |
JP2011213697A (en) | 2010-04-02 | 2011-10-27 | Astellas Pharma Inc | Anthracycline compound |
DK2807160T3 (en) | 2012-01-26 | 2019-10-14 | Angion Biomedica Corp | ANTIFIBROTIC COMPOUNDS AND APPLICATIONS THEREOF |
US9597321B2 (en) * | 2012-01-26 | 2017-03-21 | Angion Biomedica Corp. | Antifibrotic compounds and uses thereof |
US20150105380A1 (en) | 2013-09-23 | 2015-04-16 | Angion Biomedica Corp. | Methods and uses of compounds for treating disease |
-
2013
- 2013-01-26 DK DK13740566.8T patent/DK2807160T3/en active
- 2013-01-26 EP EP13740566.8A patent/EP2807160B1/en active Active
- 2013-01-26 HU HUE13740566A patent/HUE046368T2/en unknown
- 2013-01-26 WO PCT/US2013/023324 patent/WO2013112959A1/en active Application Filing
- 2013-01-26 ES ES13740566T patent/ES2748873T3/en active Active
- 2013-01-26 PT PT137405668T patent/PT2807160T/en unknown
- 2013-01-26 CA CA2862692A patent/CA2862692C/en active Active
- 2013-01-26 EP EP19187619.2A patent/EP3604307A1/en not_active Withdrawn
- 2013-01-26 PL PL13740566T patent/PL2807160T3/en unknown
- 2013-01-26 US US14/374,210 patent/US9040555B2/en active Active
- 2013-01-26 CN CN201380009183.7A patent/CN104136436B/en active Active
- 2013-01-26 AU AU2013211888A patent/AU2013211888B2/en active Active
- 2013-01-26 IN IN6869DEN2014 patent/IN2014DN06869A/en unknown
- 2013-01-26 JP JP2014554898A patent/JP6152389B2/en active Active
-
2014
- 2014-07-21 IL IL233727A patent/IL233727A/en active IP Right Grant
-
2015
- 2015-04-28 HK HK15104086.0A patent/HK1203502A1/en unknown
-
2017
- 2017-03-19 US US15/462,859 patent/US10195184B2/en active Active
- 2017-04-27 IL IL251974A patent/IL251974B/en active IP Right Grant
-
2018
- 2018-12-18 US US16/224,442 patent/US20190125731A1/en not_active Abandoned
-
2019
- 2019-08-02 US US16/530,688 patent/US11504359B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2013112959A8 (en) | 2013-09-12 |
US9040555B2 (en) | 2015-05-26 |
PT2807160T (en) | 2019-10-28 |
EP3604307A1 (en) | 2020-02-05 |
EP2807160A1 (en) | 2014-12-03 |
AU2013211888B2 (en) | 2017-08-31 |
US11504359B2 (en) | 2022-11-22 |
HUE046368T2 (en) | 2020-02-28 |
IL233727A (en) | 2017-05-29 |
EP2807160B1 (en) | 2019-07-24 |
US20180008581A1 (en) | 2018-01-11 |
CN104136436B (en) | 2019-01-01 |
CA2862692C (en) | 2021-05-04 |
US20200069662A1 (en) | 2020-03-05 |
IL251974B (en) | 2020-08-31 |
HK1203502A1 (en) | 2015-10-30 |
JP2015505543A (en) | 2015-02-23 |
PL2807160T3 (en) | 2020-03-31 |
DK2807160T3 (en) | 2019-10-14 |
US10195184B2 (en) | 2019-02-05 |
EP2807160A4 (en) | 2014-12-24 |
ES2748873T3 (en) | 2020-03-18 |
WO2013112959A9 (en) | 2015-01-15 |
US20140371234A1 (en) | 2014-12-18 |
US20190125731A1 (en) | 2019-05-02 |
CN104136436A (en) | 2014-11-05 |
IL251974A0 (en) | 2017-06-29 |
JP6152389B2 (en) | 2017-06-21 |
CA2862692A1 (en) | 2013-08-01 |
WO2013112959A1 (en) | 2013-08-01 |
AU2013211888A1 (en) | 2014-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN06869A (en) | ||
PH12016501750A1 (en) | Human plasma kallikrein inhibitors | |
PH12016502081A1 (en) | Compounds for treating spinal muscular atrophy | |
PH12018500065A1 (en) | Oxysterols and methods of use thereof | |
IN2014DN09352A (en) | ||
IN2014DN09348A (en) | ||
PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
PH12016500024A1 (en) | Bromodomain inhibitor | |
IN2015DN01156A (en) | ||
PH12014501469A1 (en) | Bromodomain inhibitors | |
MX2015011984A (en) | Dihydro-pyrrolopyridinone bromodomain inhibitors. | |
MX2014012695A (en) | Isoindolone derivatives. | |
MX2015003959A (en) | Inhibitors of histone demethylases. | |
IN2014MN02598A (en) | ||
IN2014CN02806A (en) | ||
PH12014501542B1 (en) | Substituted pyrrolidine -2- carboxamides | |
IN2014DN10670A (en) | ||
GEP20186880B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
MX2016007440A (en) | Bromodomain inhibitors. | |
IN2014DN09347A (en) | ||
TW201613864A (en) | Novel compounds | |
GB201209587D0 (en) | Therapeutic compounds | |
MX2021010297A (en) | Human plasma kallikrein inhibitors. | |
MX2017013099A (en) | Methods for the treatment of inflammatory disorders. | |
MX362879B (en) | Novel uses. |